Sayed M.S. H.
- Country
- The Netherlands
- Department
- Pulmonary medicine
Research Overview
- Phase 3 Randomized Study of Nivolumab and Ipilimumab with Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer
- Pumitamig Versus Durvalumab After Concurrent Chemoradiation in Unresectable Stage III Non-Small Cell Lung Cancer Without Progression
- Phase 3 Multicenter Trial Comparing Repotrectinib and Crizotinib in TKI-naïve ROS1-positive Advanced Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 279 of 479 partner sites.
Specializations
Oncology Focus
The investigator specializes in treating non-small cell lung cancer (NSCLC), with particular emphasis on cases involving ALK-positive mutations.
- Advanced Lung Cancer Management
- Targeted Therapy Approaches
- ALK-Positive NSCLC Treatment
Their research interests center on evaluating novel therapeutic strategies for patients with ALK-positive NSCLC, particularly in the context of treatment-naïve and minimally pretreated patients.
Precision Medicine
The investigator focuses on personalized treatment approaches through the application of targeted therapies in lung cancer treatment.
- Molecular-Based Treatment Selection
- Tyrosine Kinase Inhibitor Therapy
- Treatment Optimization
Their expertise extends to comparing the efficacy of different targeted therapeutic agents in specific patient populations.
Clinical Innovation
The investigator specializes in comparative effectiveness research in oncology therapeutics, particularly in the evaluation of novel treatment options.
- Treatment Sequencing Strategies
- Drug Safety Assessment
- Patient Response Evaluation
Their work involves assessing therapeutic outcomes in patients with specific genetic profiles to advance personalized cancer treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.